The last earnings report on September 30 showed earnings per share of -122 cents, missing the estimate of -100 cents. P/B Ratio (14.451) is normal, around the industry mean (14.843). P/E Ratio (0.000) is within average values for comparable stocks, (87.552). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.802). PYPD has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (0.000) is also within normal values, averaging (239.971). With 11.27K shares outstanding, the current market capitalization sits at 31.18M.
a clinical stage biopharmaceutical company focusing on the development, manufacture, and commercialization of administered therapies to improve surgical outcomes